PETALING JAYA: Affordable Hepatitis C treatment will soon be available for patients once trials on generic drugs are completed.
The non-profit Drugs for Neglected Diseases initiative (DNDi), of which the Malaysian Health Ministry is a founding member, and Egyptian drug manufacturer Pharco Pharmaceuticals on Wednesday signed agreements covering clinical testing and scale-up of a Hepatitis C treatment regimen at a price of just under US$300 (RM1,166) at the International Liver Congress 2016 in Barcelona, Spain.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
